According to Zhitong Financial App News, Wanbang Pharmaceutical (301520.SZ) issued an announcement on abnormal stock trading fluctuations and risk alerts, saying that the company recently observed that the company's recent media and stock community reports that information relating to the company's promotion of the core pipeline to innovate the drug huxerine A controlled-release tablets and sign cooperation agreements for new drugs such as fever is false; the company's semi-annual results for 2026 have not been disclosed to the outside world, nor has it released a performance forecast yet.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.